Evidence map›Paper›PMID 25945971›Full record

ArticleCell cycle (Georgetown, Tex.)2015

DEK over-expression promotes mitotic defects and micronucleus formation.

Marie C Matrka, Robert F Hennigan, Ferdinand Kappes, Monica L DeLay, Paul F Lambert, Bruce J Aronow, Susanne I Wells

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Role of the DEK oncogene in the development of squamous cell carcinoma.International journal of clinical oncology · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Marie C Matrkaa Cancer and Blood Diseases Institute; Cincinnati Children's Hospital Medical Center and University of Cincinnati ; Cincinnati , OH USA.
Robert F Hennigana Cancer and Blood Diseases Institute; Cincinnati Children's Hospital Medical Center and University of Cincinnati ; Cincinnati , OH USA.
Ferdinand Kappesb Department of Biological Sciences ; Xi'an Jiaotong-Liverpool University , Suzhou , Jiangsu Province , China.
Monica L DeLayd Division of Rheumatology; Cincinnati Children's Hospital Medical Center ; Cincinnati , OH USA.
Paul F Lamberte McArdle Laboratory for Cancer Research; University of Wisconsin-Madison School of Medicine and Public Health ; Madison , WI USA.
Bruce J Aronowf Biomedical Informatics; Cincinnati Children's Hospital Medical Center ; Cincinnati , OH USA.
Susanne I Wellsa Cancer and Blood Diseases Institute; Cincinnati Children's Hospital Medical Center and University of Cincinnati ; Cincinnati , OH USA.
Cincinnati Children's Hospital Medical Center · USOncology Hematology Care · USBiomedical Informatics Research Center Antwerp · BECenter for Cancer Research · USXi’an Jiaotong-Liverpool University · CN

Funding

Stem Cell/Organoid and Genome Editing CoreP30DK078392 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI Alexander Miethke · 2007 to 2026
$24.4M
ROLE OF ANGPTL4, AN ANGIOGENIC MEDIATOR, IN ARTHRITISP30AR047363 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI FLICK, MATTHEW J. · 2001 to 2015
$9.2M
Cincinnati Center for Excellence in Molecular HematologyP30DK090971 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI ZHENG, YI · 2010 to 2015
$4.0M
Role and Regulaton of the Human DEK Proto-OncogeneR01CA116316 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI WELLS, SUSANNE I · 2006 to 2016
$2.9M
NCI NIH HHS R01 CA116316NIAMS NIH HHS NIH AR-47363NIDDK NIH HHS NIH DK78392NIDDK NIH HHS NIH DK90971
6 · The paper itself

Abstract

The DEK gene encodes a nuclear protein that binds chromatin and is involved in various fundamental nuclear processes including transcription, RNA splicing, DNA replication and DNA repair. Several cancer types characteristically over-express DEK at the earliest stages of transformation. In order to explore relevant mechanisms whereby DEK supports oncogenicity, we utilized cancer databases to identify gene transcripts whose expression patterns are tightly correlated with that of DEK. We identified an enrichment of genes involved in mitosis and thus investigated the regulation and possible function of DEK in cell division. Immunofluorescence analyses revealed that DEK dissociates from DNA in early prophase and re-associates with DNA during telophase in human keratinocytes. Mitotic cell populations displayed a sharp reduction in DEK protein levels compared to the corresponding interphase population, suggesting DEK may be degraded or otherwise removed from the cell prior to mitosis. Interestingly, DEK overexpression stimulated its own aberrant association with chromatin throughout mitosis. Furthermore, DEK co-localized with anaphase bridges, chromosome fragments, and micronuclei, suggesting a specific association with mitotically defective chromosomes. We found that DEK over-expression in both non-transformed and transformed cells is sufficient to stimulate micronucleus formation. These data support a model wherein normal chromosomal clearance of DEK is required for maintenance of high fidelity cell division and chromosomal integrity. Therefore, the overexpression of DEK and its incomplete removal from mitotic chromosomes promotes genomic instability through the generation of genetically abnormal daughter cells. Consequently, DEK over-expression may be involved in the initial steps of developing oncogenic mutations in cells leading to cancer initiation.

Indexed as

AnaphaseAneuploidyAnimalsBlotting, WesternCell DivisionCell NucleusChromatinChromosomal InstabilityChromosomal Proteins, Non-HistoneChromosomesFlow CytometryHumansInterphaseMiceMitosisOncogene ProteinsChromatinChromosomal Proteins, Non-HistoneDEK protein, humanOncogene ProteinsPoly-ADP-Ribose Binding Proteinsaneuploidycancerchromosome instabilityDEKmicronucleimitosismitotic defects

Identifiers

PMID25945971
PMCPMC4825741
OpenAlexW1820101493

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.